Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Diabetes (Type 2) — Weekly Report — November 2, 2026

Home/Health Insights/Diabetes (Type 2) — November 2 – November 9, 2026
Vol. 7 · No. 46
DoctiPlus Care · Weekly Brief on Diabetes (Type 2)
Updated Sunday · November 15, 2026
Diabetes (Type 2) · November 2 – November 9, 2026

Diabetes (Type 2)
Weekly Report

This week's data 37 new clinical trials registered across 10 countries, with 1,959 trials actively recruiting patients worldwide.
Week of November 2 – November 9, 2026
  • 37 new clinical trials registered across 10 countries.
  • 1,959 trials actively recruiting patients worldwide.
  • Notable trial: Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition (1600 patients).
  • 337 new research papers published.
  • Drug safety: Most reported effect across tracked medications (metformin, semaglutide, sitagliptin, empagliflozin, insulin glargine) was Off Label Use.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · November 2 – November 9, 2026
New Trials This Week
37.
registered Nov 2–Nov 9
Recruiting Now
1,959
active trials seeking patients
Countries
10
with active trials this week
Papers Published
337
new studies this week
Phase 3 Trials
4
late-stage trials this week
Fig. 01

Trials by country

Count · November 2 – November 9, 2026
China
39
United States
9
Not specified
6
India
6
France
3
Poland
2
Pakistan
2
Italy
2
Switzerland
2
Turkey (Türkiye)
2
0 10 20 30 39
total
Fig. 02

Trials by phase

Distribution · November 2 – November 9, 2026

New clinical trials registered this week for Diabetes (Type 2). Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

37 trials registered for Diabetes (Type 2). Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes Diabetes (Type 2) · Jiangsu HengRui Medicine Co., Ltd. (NCT07920939) Phase 3 Not Yet Recruiting 450 China
02 Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals Diabetes (Type 2) · National University Polyclinics, Singapore (NCT07922837) Other Active Not Recruiting 57 Singapore
03 Safety and Efficacy of the Fully Closed Loop iLet Bionic Pancreas in Adults With Type 1 and Type 2 Diabetes Diabetes (Type 2) · Beta Bionics, Inc. (NCT07911566) Other Not Yet Recruiting 400 N/A
04 A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes Diabetes (Type 2) · BrightGene Bio-Medical Technology Co., Ltd. (NCT07918625) Phase 2 Not Yet Recruiting 160 China
05 SWitching to Appropriate Prescription in Cardiovascular-Kidney-Metabolic Syndrome Diabetes (Type 2) · Kaiser Permanente (NCT07910968) Other Not Yet Recruiting 1,200 United States
06 The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes Diabetes (Type 2) · Medical University of Bialystok (NCT07913685) Phase 4 Completed 83 Poland
07 Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy Diabetes (Type 2) · Medical University of Vienna (NCT07921940) Other Active Not Recruiting 40 Austria
08 Continuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic Foot. Diabetes (Type 2) · Solsius (NCT07910721) Other Recruiting 60 France
09 Lifestyle Medicine for Type 2 Diabetes Remission in Pakistan Diabetes (Type 2) · Green International University (NCT07912944) Other Recruiting 178 Pakistan
10 AI-Based Model for Predicting Type 2 Diabetes Risk Using Lifestyle Factors Among Senior Nursing Students Diabetes (Type 2) · Alexandria University (NCT07916428) Other Not Yet Recruiting 200 Egypt
11 Beta-2-Trace Protein in Diabetic Nephropathy Diabetes (Type 2) · Assiut University (NCT07919795) Other Not Yet Recruiting 80 N/A
12 A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes Diabetes (Type 2) · AstraZeneca (NCT07922330) Phase 3 Not Yet Recruiting 330 China
13 Safety and Effect of Peripheral Nerve Decompression Combined With Peripheral Nerve Stimulation for Painful Diabetic Peripheral Neuropathy Diabetes (Type 2) · Qilu Hospital of Shandong University (NCT07911410) Other Recruiting 100 China
14 A Nurse-Led Personalized Self-Management Counseling Intervention to Improve Medication Adherence and Glycemic Control in Adults With Type 2 Diabetes: A Randomized Controlled Trial Diabetes (Type 2) · University of Basrah (NCT07920042) Other Not Yet Recruiting 128 Iraq
15 Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes Diabetes (Type 2) · University of the Pacific (NCT07920341) Other Not Yet Recruiting 60 United States
16 Community Health Worker Nutrition Self-Management Support for Cardio-Kidney-Metabolic Health Diabetes (Type 2) · Florida International University (NCT07918508) Other Not Yet Recruiting 200 United States
17 Pilates vs. Core Stabilization for Balance and Mobility in Elderly Type 2 Diabetics Diabetes (Type 2) · Beni-Suef University (NCT07920653) Other Not Yet Recruiting 40 N/A
18 Effects of a Multispecies Probiotic on Metabolic, Liver, and Gut Health Diabetes (Type 2) · University of Bari (NCT07909772) Other Completed 56 Italy
19 Clinical Research Trial to Study Insulin Sensitivity Using Automated Glucose Clamp Technology Diabetes (Type 2) · Profil Institut für Stoffwechselforschung GmbH (NCT07913698) Other Not Yet Recruiting 50 United States
20 Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Diabetes (Type 2) · Beckey Trinh (NCT07922148) Phase 2 Not Yet Recruiting 44 Switzerland
21 A Nurse-Led Digital Coaching Program to Improve Blood Sugar Control in Adults With Type 2 Diabetes Diabetes (Type 2) · Alexandria University (NCT07916584) Other Not Yet Recruiting 160 Bahrain
22 Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Diabetes (Type 2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (NCT07915596) Other Completed 792 Bangladesh
23 STRONG: SMART Trial Diabetes (Type 2) · Yale University (NCT07920588) Other Not Yet Recruiting 360 American Samoa
24 A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2) Diabetes (Type 2) · Pfizer (NCT07915609) Phase 3 Recruiting 756 United States
25 Continuous Glucose Monitoring Systems in People With Type 2 Diabetes Not Treated With Insulin Diabetes (Type 2) · Medical University of Bialystok (NCT07919236) Other Recruiting 50 Poland
26 Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle Intervention Diabetes (Type 2) · Beijing Supreme Life Pharmaceutical Technology Co., Ltd. (NCT07920640) Phase 2 Not Yet Recruiting 150 China
27 Effects of Individualized Preferred and Higher Treadmill Walking Speeds Followed by Cognitive Training on Heart Rate Variability, Gait Performance, and Motor-Cognitive Function in Older Adults With Type 2 Diabetes: A Randomized Controlled Trial With 4-Week Retention Follow-up Diabetes (Type 2) · University of Phayao (NCT07920510) Other Active Not Recruiting 60 Thailand
28 Outpatient Pramlintide Study Diabetes (Type 2) · Oregon Health and Science University (NCT07914621) Other Not Yet Recruiting 26 N/A
29 Relationship Between Insulin Dose and Complications in Type 1 Diabetes Diabetes (Type 2) · Rachel Miller (NCT07911033) Other Not Yet Recruiting 80 United States
30 LEANDIP: Lean Diabetes in Asian Indians Diabetes (Type 2) · Diabetes Foundation, India (NCT07918170) Other Not Yet Recruiting 151 N/A
31 Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition Diabetes (Type 2) · Fondation Net-Care.ch (NCT07916753) Other Not Yet Recruiting 1,600 Switzerland
32 Differentiating Heart Disease Between Adult-onset Autoimmune and Type 2 Diabetes Diabetes (Type 2) · University of Roma La Sapienza (NCT07911007) Other Recruiting 200 Italy
33 IL-4 and IL-17 Responses to Periodontal Therapy in Patients With Type 2 Diabetes Diabetes (Type 2) · Dicle University (NCT07917936) Other Completed 45 Turkey (Türkiye)
34 A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin Diabetes (Type 2) · Jiangsu HengRui Medicine Co., Ltd. (NCT07913061) Phase 3 Not Yet Recruiting 680 China
35 Comparison of Functional Inspiratory Muscle Training and Combined Exercise Training in Individuals With Type 2 Diabetes Diabetes (Type 2) · İrem Çaylak Yetüt (NCT07921901) Other Not Yet Recruiting 39 Turkey (Türkiye)
36 Obesity-Related Indices and Albuminuria in Type 2 Diabetes Diabetes (Type 2) · Assiut University (NCT07922694) Other Not Yet Recruiting 349 N/A
37 A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus Diabetes (Type 2) · Shenzhen Salubris Pharmaceuticals Co., Ltd. (NCT07923357) Phase 2 Not Yet Recruiting 364 China
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Diabetes (Type 2). These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
metformin Diarrhoea 2,273
semaglutide Nausea 2,980
sitagliptin Nausea 332
empagliflozin Nausea 836
insulin glargine Off Label Use 4,782

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Diabetes (Type 2). If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

337 papers

Recently published peer-reviewed studies related to Diabetes (Type 2), sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Hormones, glycaemia and innate immunity: correlates of NK cell dysfunction in type 2 diabetes. Omer ZK et al. 10.1515/hmbci-2026-0069
View abstract

OBJECTIVES: Type 2 diabetes mellitus (T2DM) is linked to impaired natural killer (NK) cell function and altered sex hormone homeostasis. We examined the associations of HbA, sex hormones and NK-cell subsets with peripheral blood mononuclear cell (PBMC) cytotoxicity. METHODS: In this cross-sectional study, 58 patients with T2DM and 62 metabolically healthy controls were enrolled. PBMC cytotoxicity (specific lysis of K-562-GFP target cells, an NK cell-associated readout) was measured by flow cytometry. Serum estradiol, testosterone and HbA were measured, and NK-cell subsets were quantified by flow cytometry. In an exploratory sub-cohort of 16 patients undergoing bariatric surgery, omental adipose tissue (OAT)-derived immune cells were compared with paired PBMCs. RESULTS: There was a reduction in PBMC cytotoxicity for men with T2DM compared to control men and for women compared to men with T2DM. Multiple regression analysis showed that the cortisol level and PBMC cytotoxicity were inversely correlated (adjusted R=0.218), while the testosterone level and percentage of CD56CD16 NK-cells were positively correlated (adjusted R2=0.218). The OAT-derived cells proved to be more cytotoxic than matched PBMCs (p=0.0005). CONCLUSIONS: These are theory generating associations. The cross-sectional design and limited number of children in the OAT sub-cohort and the lack of surgical control group in the non-diabetic population limit the ability to make causal inferences and need to be confirmed in future prospective studies.

Hormone molecular biology and clinical investigation 2026 Nov 9 PubMed
02 Factors Associated With Extended Resection (Cecal Resection or Right Hemicolectomy) in Patients With Acute Appendicitis at a Tertiary Private Hospital: A Retrospective Cohort Study. Silva-Ramos CS et al. 10.7759/cureus.119274
View abstract

INTRODUCTION: Acute appendicitis may require surgical procedures beyond conventional appendectomy, including cecal resection and right hemicolectomy. This study aimed to identify clinical factors associated with extended resection in adults undergoing surgery for acute appendicitis. METHODS: This retrospective, single-center cohort study included 360 adults treated surgically for acute appendicitis at a tertiary care hospital between 2018 and 2023. Extended resection was defined as cecal resection or right hemicolectomy. Associations were assessed using univariate analyses and multivariable logistic regression adjusted for age, symptom duration, previous abdominal surgery, diabetes mellitus, and hypertension. Appendicitis severity was evaluated in a secondary model using grouped phases. Missing data were not imputed. The study received ethics committee approval (2024-EXT-871). RESULTS: Extended resection occurred in 50 of 351 patients with available outcome data (14.2%). Longer symptom duration (adjusted odds ratio (aOR) 1.185; 95% confidence interval (CI) 1.004-1.398; p=0.045) and older age (aOR 1.022; 95% CI 1.001-1.045; p=0.045) were associated with extended resection in the primary model. In the secondary model, advanced appendicitis phases were strongly associated with extended resection (aOR 10.273; 95% CI 4.694-22.481; p<0.001). CONCLUSION: Longer symptom duration was associated with extended resection, including after adjustment for grouped appendicitis severity. These findings warrant cautious interpretation given the retrospective design and limited number of events.

Cureus 2026 Nov PubMed
03 The Role of Health Coaches on a Clinical Research Team: Development & Implementation of a Health Coach-Informed Research Model During User Testing of a Lupus Whole Health Intervention. Baker LS et al. 10.1177/15598276261502276
View abstract

The purpose of this paper is to describe the impact of a health coach-informed research model within an interdisciplinary lupus research team during intervention development and user testing. Health coaches are increasingly integrated into lifestyle medicine interventions for chronic disease management, but their role has largely been described in intervention delivery, with limited research on their integration during development. The Lupus WHEEL (Whole Health Empowerment for Endotypes of Lupus) program, is an interdisciplinary intervention designed for systemic lupus erythematosus (SLE), adapted from a shared medical appointment model originally developed for type 2 diabetes. Two National Board-Certified Health and Wellness Coaches (NBC-HWC) served as active interdisciplinary research team members across three phases: pre-user testing, during user testing, and post-user testing. Integration was supported by disease-specific clinical immersion, weekly interdisciplinary team meetings, and a coach-developed debrief tool for real-time observations. Throughout the study, coach integration extended beyond intervention delivery to include program refinement, scope-of-practice review, structured debriefing, and shared research team decision-making, resulting in restructured session sequencing, revised goal tracking, and content adjustment based on participant feedback. Notable insights were that earlier integration of health coaches expanded their role beyond delivery, fostered bidirectional learning, and highlighted the value of clinical immersion, offering a replicable framework for lifestyle medicine research teams. Trial Registration: Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE (WHEEL). ClinicalTrials.gov ID: NCT06720584. URL: https://clinicaltrials.gov/study/NCT06720584. Unique Protocol ID (IRB): Pro00111699.

American journal of lifestyle medicine 2026 Nov 6 PubMed
04 A Journey Map of Health Behaviour Decision-Making Among Patients with Type 2 Diabetes Mellitus Who are Repeatedly Hospitalized: A Longitudinal Qualitative Study. Mao H et al. 10.2147/JMDH.S646999
View abstract

BACKGROUND: Health behaviour decision-making is central to type 2 diabetes mellitus management, but remains complex and context dependent after repeated hospitalisations. Research has focused on health behaviours and associated factors, overlooking patient-centred decision-making across care stages and limiting stage-specific decision support and continuity-of-care strategies. METHODS: A longitudinal qualitative study was conducted in mainland China, with data collected from October 2025 to March 2026. 16 patients with type 2 diabetes mellitus who had experienced repeated hospitalisations were included and participated in repeated semi-structured interviews across three stages: pre-admission (T1), hospitalisation (T2), and home management (T3). Interviews were conducted on the second day of hospitalisation, one day before discharge, and three months after discharge. The interviews explored decision-making behaviours, support needs, emotional experiences, and pain points. Longitudinal analysis involved within-participant comparison across the three care stages, followed by cross-case synthesis to identify recurrent and divergent patterns of change. The findings were then integrated into a time-based visual journey map of health behaviour decision-making. RESULTS: Four stage-specific trajectories were synthesised from the longitudinal interview data within four dimensions initially identified through preliminary patient observations: (1) behavioural transition from preference-driven care-seeking decisions to structured treatment adherence and fragile self-management; (2) evolving support needs from seeking trusted decision anchors to seeking structured empowerment and transition preparation, and finally to seeking continuous and accessible out-of-hospital support; (3) emotional evolution from self-blame after initially neglecting the illness, to fragile stability, and ultimately to acceptance and coexistence with the disease under long-term burden; and (4) phase-specifc pain points, including decision-making impeded by multiple information dilemmas before admission, insufficient motivation for sustained self-management during hospitalisation, and support discontinuity with practical burdens during home management. CONCLUSION: This study extends the application of patient journey mapping to understanding health behaviour decision-making among patients with T2DM who experience repeated hospitalisations. By identifying critical disruptions in decision-making, unmet needs, and barriers to sustained management, the journey map offers actionable insights for designing stage-specific, patient-centred decision-support and continuity-of-care interventions, with particular relevance to nurse-led clinical practice.

Journal of multidisciplinary healthcare 2026 PubMed
05 Gestational Diabetes Mellitus and Birth Weight: A Bidirectional Mendelian Randomization and Cohort Study in China. Li X et al. 10.2147/DMSO.S653174
View abstract

BACKGROUND: Gestational diabetes mellitus (GDM) is regarded as a driver of fetal macrosomia, yet observational estimates of its effect on birth weight (BW) are vulnerable to confounding. Whether GDM causally shapes fetal growth, and through which shared biology, remains unresolved. METHODS: We performed a bidirectional two-sample Mendelian randomization (MR) using FinnGen R11 GDM (16,802 cases) and the EGG Consortium birth-weight GWAS (n=286,868), with inverse-variance weighted (IVW, primary), MR-Egger, weighted median, weighted mode, RAPS estimators, MR-PRESSO and Bayesian colocalization. Multi-omics evidence (GSE92772, ST001948, INTERVAL cis-pQTLs) was integrated as hypothesis-generating evidence. In a cohort of 24,448 singleton pregnancies, linear and logistic regression, bootstrap mediation, and double/debiased machine learning (DML) were performed for verification. RESULTS: The primary IVW estimate for GDM to BW was null (β=-0.004, P=0.889) under extreme heterogeneity, and robust estimators showed nominally positive signals. Seven of 21 instruments flagged as outliers overlapping six colocalizing loci. Therefore, it is impossible to precluding a reliable causal interpretation. Reverse MR (BW to GDM) was exploratory (five instruments, all outliers). Colocalization identified six loci (, , , , , ) with evidence of a shared causal variant (PP.H4≥0.5). All established islet beta-cell/insulin-secretion genes suggested shared upstream biology. In the cohort, GDM was associated with higher rates of macrosomia (OR 1.21) and lower birth weight (LBW, OR 1.45). The association of macrosomia was largely attenuated after adjustment for maternal BMI and lipids (OR 1.01, P=0.913). Using bidirectional mediation analysis, five candidate mediators (BMI, TG, HDL-C, LDL-C, and TG/HDL-C ratio) were identified as significant mediators in both directions. Moreover, hypertensive disorders showed the largest associations with LBW (PE β=-0.204; GH β=-0.067) in DML analyses. CONCLUSIONS: Evidence for a consistent causal effect of GDM on birth weight remains inconclusive. The observational association of macrosomia was largely explained by maternal metabolic status. The shared insulin-secretory biology more plausibly reflects genetic pleiotropy than a direct causal pathway. Hypertensive disorders showed stronger associations with birth weight reduction than GDM, supporting integrated management of glycemia, BMI, lipids and blood pressure.

Diabetes, metabolic syndrome and obesity : targets and therapy 2026 PubMed
06 Effectiveness of incretin receptor agonists compared to metreleptin in partial lipodystrophy: a retrospective study. Podyma BM et al. 10.1210/jendso/bvag248
View abstract

CONTEXT: Lipodystrophy syndromes are rare disorders of abnormal fat distribution and metabolic disease. The only approved therapy for generalized lipodystrophy is recombinant leptin (metreleptin), which is not approved for partial lipodystrophy. Recent data suggest efficacy of glucagon-like peptide-1 receptor agonists and glucagon-like peptide-1 receptor agonist/glucose-dependent insulinotropic polypeptide (GIP) dual agonists (collectively referred to as incretins) to treat complications of lipodystrophy. OBJECTIVE: To compare metabolic outcomes of incretin therapies vs metreleptin in partial lipodystrophy. DESIGN: Retrospective review of patients who received metreleptin as part of a clinical trial and incretins during routine care under a natural history study. SETTING: NIH Clinical Center. PATIENTS: Twelve female patients with partial lipodystrophy, aged 16-85 years. All but 1 patient had diabetes. INTERVENTION: Eleven patients with partial lipodystrophy were treated with metreleptin (mean duration 104 ± 38 months) before switching to incretin therapy (duration 32 ± 13 months). A twelfth patient took metreleptin and an incretin concurrently. MAIN OUTCOME MEASURES: Outcome measures included hemoglobin A1c, insulin dose, Matsuda index, insulinogenic index, disposition index, fasting glucose and insulin, homeostatic model of beta cell function (HOMA-B), homeostatic model assessment of insulin resistance (HOMA-IR), weight, lipids, liver elastography, and liver steatosis. RESULTS: Hemoglobin A1c was significantly lower during incretin vs metreleptin treatment (mean difference -1.1 ± 0.4%, range -4.75% to -0.1%, = .005), associated with modest weight reduction (mean difference -1.5 ± 3.9 kg, range -10.4 to 3 kg, = .046). Most other metabolic parameters did not differ significantly between treatment periods. CONCLUSION: In patients with partial lipodystrophy, incretins may provide better diabetes control than metreleptin, with comparable control of other metabolic parameters.

Journal of the Endocrine Society 2026 Dec PubMed
07 Healthcare Professionals' Priorities for Guidelines on Deprescribing Antihyperglycemics: A Mixed-Methods Study. Chapman AJ et al. 10.1007/s40266-026-01345-2
View abstract

BACKGROUND: For older adults living with frailty and type 2 diabetes, reassessing the appropriateness of medications is important. This may include consideration of deprescribing (reducing or stopping) antihyperglycemic medications. Our deprescribing.org team created a guideline for deprescribing antihyperglycemics in 2017. To inform a guideline update, we conducted a prioritization exercise to ensure our update addresses current healthcare professional (HCP) needs and priorities. OBJECTIVE: The aim was to establish HCP priorities with regards to the guideline topics, outcomes, and knowledge translation materials included with the 2017 guideline and identify gaps in the content to be added to the update. METHODS: We conducted a sequential explanatory mixed-methods study between April and June 2025, including a survey open to participants globally, followed by focus groups open to participants in Canada. Quantitative survey data were analyzed using descriptive statistics. Qualitative data within the survey and focus group discussions were analyzed using summative content analysis and conventional content analysis, respectively. RESULTS: All guideline topics proposed in the survey were considered either "extremely important" or "important" by the majority of participants. The outcome considered most critical for decision-making when deprescribing was clinical symptoms of hypoglycemia (91%). As a knowledge translation tool, a decision-support algorithm was considered important or extremely important by 84% of respondents. Qualitative findings highlighted considerations for incorporating novel antihyperglycemic agents into deprescribing decisions, cost implications for the patient, and knowledge translation resources (e.g., reporting templates) to support clear communication between prescribers, and patient education materials. CONCLUSIONS: The topics and outcomes included in deprescribing.org's 2017 antihyperglycemic deprescribing guideline were all considered important or extremely important by HCPs and therefore we will recommend that these be carried forward into the new guideline. Next steps will include reporting HCP priorities to the guideline panel and updating the systematic review for the guideline.

Drugs & aging 2026 Nov 7 PubMed
08 Corrigendum to "The attenuation of gut microbiota-derived short-chain fatty acids elevates lipid transportation through suppression of the intestinal HDAC3-H3K27ac-PPAR-γ axis in gestational diabetes mellitus" [The Journal of Nutritional Biochemistry 133 (2024) 109708]. Chen H et al. 10.1016/j.jnutbio.2026.110526 The Journal of nutritional biochemistry 2026 Nov 7 PubMed
09 Diabetic ketoacidosis associated with the reuse of single-use materials in a patient with type 1 diabetes mellitus treated with an advanced hybrid closed-loop system: A case report. López Calles A et al. 10.1016/j.endien.2026.501820
View abstract

Diabetic ketoacidosis (DKA) remains a potentially serious complication in individuals with type 1 diabetes mellitus, even in those treated with continuous subcutaneous insulin infusion systems. We describe the case of a 45-year-old woman using an advanced hybrid closed-loop system who was admitted with an episode of mild DKA in the absence of identifiable precipitating factors. Metabolic correction was performed according to current recommendations, with a favorable clinical course. Subsequent review of continuous glucose monitoring data and insulin delivery records revealed persistent hyperglycemia secondary to malfunction of the infusion device. This was associated with structural deterioration of a reused insulin cartridge designed for single use, in the context of a shortage of original supplies. This case highlights the importance of infusion materials in pump therapy safety, the limitations of automated systems in detecting mechanical failures, and the need for safe alternative strategies in situations of supply disruption.

Endocrinologia, diabetes y nutricion 2026 Nov 7 PubMed
10 Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience. Patel SK et al. 10.1016/j.diabres.2026.113648
View abstract

Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has become an important therapeutic agent for type 2 diabetes mellitus (T2DM), obesity, and associated cardiometabolic complications. Its prolonged pharmacological activity and availability as subcutaneous and oral formulations have supported extensive clinical development across diverse populations. This review critically evaluates Phase 3, Phase 3a, and Phase 3b clinical trials (CTs) assessing the efficacy, safety and therapeutic utility of semaglutide, with an emphasis on the SUSTAIN, PIONEER, STEP, SELECT, FLOW, SOUL and related programmes. Eligible trials were assessed according to study design, registration, treatment duration, population characteristics, interventions, comparators, primary endpoints, adverse events (AEs) and clinical significance. Collectively, the evidence demonstrates clinically meaningful improvements in glycaemic control and body weight, as well as cardiovascular and renal benefits, in selected populations. Evidence from obesity and post-bariatric studies further supports its expanding therapeutic role beyond conventional glucose management. Gastrointestinal events, particularly nausea, vomiting, diarrhoea and constipation, were the predominant adverse effects, while overall tolerability remained consistent with the established GLP-1RA profile. However, differences in populations, treatment duration, comparators and endpoint definitions highlight important evidence gaps. This review synthesises Phase 3 clinical evidence to define the evolving therapeutic position, safety profile and future research priorities for semaglutide.

Diabetes research and clinical practice 2026 Nov 7 PubMed
11 Plasma proteomic profiling reveals mediating proteins and preventive targets linking ambient air pollution to type 2 diabetes incidence: a prospective cohort study. Lin Z et al. 10.1016/j.envpol.2026.129476
View abstract

Ambient air pollution has been associated with type 2 diabetes (T2D), but the underlying biological mechanisms remain poorly understood. We included 44,917 participants with 2,911 plasma proteins from a large prospective cohort and followed them for incident T2D. Long-term PM, NO, NO, and SO exposures were estimated via bilinear interpolation. Cox regressions assessed air pollutant-T2D associations. Elastic net regression identified air pollution-associated proteins and constructed a protein score. Mediation analyses identified top-mediating proteins. Functional and PPI analyses identified hub proteins. Druggability was screened using two drug databases, with binding potential evaluated by molecular docking across seven small-molecule databases. During 13.64 years of follow-up, 3,193 incident T2D cases occurred. Per IQR increase in PM, NO, NO, and SO was associated with 5%-14% higher T2D risk. We identified 187 proteins mediating the PM-T2D association, 61 for NO, 66 for NO, and 14 for SO. The protein score mediated 31.69% (PM), 18.06% (NO), 16.81% (NO), and 19.71% (SO) of the associations. Functional and PPI analyses revealed these proteins function through cytokine-cytokine receptor interactions, chemokine signaling, leukocyte migration, and inflammation-related pathways. We further identified 13 targeted proteins with approved drugs (4 in DrugBank, 4 in Therapeutic Target Database). Molecular docking indicated 5 have potential small-molecule binders. This study identified potential biological pathways and candidate mediators linking air pollution to T2D, particularly through inflammatory and immune-related pathways mediated by plasma proteins, and identified potential intervention targets, offering opportunities for drug repurposing and precise prevention.

Environmental pollution (Barking, Essex : 1987) 2026 Nov 7 PubMed
12 The pathological role of chemokines and chemokine receptors in diabetic vascular disease. Lan TY et al. 10.1016/j.cyto.2026.157226
View abstract

Diabetic vascular diseases, which include microvascular and macrovascular diseases, are a common complication of diabetes mellitus. Both chemokines and their receptors are involved in the pathophysiological process of diabetic vascular diseases, given their diverse functions. Crucially, when evaluating these chemokine networks, it is essential to distinguish descriptive clinical and bioinformatic biomarker observations from functional causal mechanisms established through in vitro and in vivo interventional studies, as observational concentration changes alone do not inherently demonstrate a direct pathogenic role or identify a therapeutic target. In this review, we examine recent studies and provide an overview of the mechanisms underlying chemokine-mediated signaling in diabetic microvascular and macrovascular diseases. We conclude that while circulating chemokines primarily serve as diagnostic or prognostic biomarkers, specific functional chemokine axes represent viable therapeutic targets for diabetic vascular complications.

Cytokine 2026 Nov 7 PubMed
13 PACAP attenuates diabetic neuropathic pain by modulating ERK-PGC1α- associated mitochondrial homeostasis. Cao D et al. 10.1016/j.neurot.2026.e01112
View abstract

Diabetic neuropathic pain is a debilitating complication of diabetes for which disease-modifying therapies remain limited. Pituitary adenylate cyclase-activating polypeptide (PACAP) has been implicated in neuroprotection and metabolic regulation, but its role in diabetic neuropathic pain remains unclear. Here, we found that patients with diabetic neuropathic pain had reduced serum PACAP-38 levels and elevated pro-inflammatory cytokines compared with patients with diabetes mellitus alone. In streptozotocin-induced diabetic neuropathic pain (DNP) mice, PACAP partially improved body weight recovery but did not markedly reduce fasting hyperglycemia, glucose tolerance or pancreatic islet injury. Importantly, PACAP improved gait performance, attenuated mechanical, thermal, and cold hypersensitivity, and preserved intraepidermal nerve fibers. Transcriptomic and validation analyses showed that diabetic neuropathic pain was associated with endothelial impairment, hypoxia-related signaling, mitochondrial alterations, and redox imbalance in dorsal root ganglia. PACAP treatment partially modulated DNP-related transcriptional changes, including those linked to mitochondrial metabolism, oxidative stress-related processes, and neuronal function. Mechanistically, PACAP increased ERK phosphorylation and PGC1α expression, enhanced mitochondrial biogenesis-related responses, preserved mitochondrial ultrastructure, and improved mitochondrial membrane potential. ERK inhibition with U0126 attenuated PACAP-mediated mitochondrial protection and analgesic effects. These findings suggest that PACAP alleviates DNP through an ERK-PGC1α-associated mechanism that contributes to the restoration of mitochondrial homeostasis in sensory neurons, rather than by substantially correcting systemic hyperglycemia.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2026 Nov 7 PubMed
14 Insulin resistance blood markers predict clinical milestones in early-stage Parkinson's Disease. Buttarazzi V et al. 10.1016/j.parkreldis.2026.109036
View abstract

INTRODUCTION: Parkinson's disease (PD) is characterized by clinical heterogeneity and substantial variability in disease course. Insulin resistance (IR) has been proposed as a contributor to PD progression, although its prognostic role remains unclear. We investigated whether blood surrogate markers of IR, the triglyceride/high-density lipoprotein cholesterol ratio (TG/HDL-C) and triglyceride-glucose index (TyG), could predict the development of clinical milestones (CM) in early-stage PD patients (ePD). MATERIALS AND METHODS: this longitudinal study included 98 ePD patients and 81 matched controls. At baseline, participants underwent clinical examination and blood sampling, allowing calculation of TG/HDL-C and TyG. Patients were followed for at least one year and stratified according to CM occurrence, defined as the first visit at which cognitive impairment, recurrent falls or visual hallucinations were documented. An Elastic Net-penalized Cox model with bootstrap resampling was used to identify robust prognostic variables while minimizing overfitting. Selected variables were then entered into a multivariable Cox proportional hazards model. Time-dependent ROC analysis assessed the prognostic performance of TG/HDL-C. RESULTS: baseline TG/HDL-C levels were significantly higher among patients experiencing CM. Notably, this marker emerged as the only independent predictor of CM development in the multivariable analysis (HR = 2.03, p < 0.001). Higher values were also associated with reduced CM-free survival and showed moderate prognostic discrimination at 60 months (AUC = 0.737), with a cutoff of 1.63 identifying patients at increased risk of CM. CONCLUSION: TG/HDL-C, a surrogate marker of IR, may provide prognostic information and help identify ePD patients at risk of worse disease progression.

Parkinsonism & related disorders 2026 Nov 4 PubMed
15 Effect of a nurse-led supported self-care intervention on cardiometabolic outcomes in adults with type 2 diabetes: a quasi-experimental study. Brito GS et al. 10.1016/j.gerinurse.2026.104434
View abstract

BACKGROUND: Supported self-care interventions are increasingly used in diabetes management; however, evidence regarding their impact on cardiometabolic outcomes in primary care remains limited. OBJECTIVE: To examine changes in cardiometabolic indicators following a nurse-led supported self-care intervention in adults with type 2 diabetes. METHODS: A single-group pre-post study derived from a larger quasi-experimental project was conducted between March and November 2023 at a Family Health Unit in Central-West Brazil. Participants received three monthly nurse-led supported self-care consultations and two telephone follow-ups. Clinical and anthropometric measures were assessed at baseline, during the intervention, and post-intervention, whereas HbA1c, triglycerides, TyG, and TyG-WC were assessed at baseline and post-intervention. Data were analyzed using Friedman, Wilcoxon signed-rank, and McNemar tests, as appropriate. RESULTS: Twenty-nine participants completed follow-up and were included in the final analysis. Significant reductions were observed in waist circumference, systolic blood pressure, TyG, and TyG-WC. No significant change in HbA1c was observed between baseline and post-intervention. CONCLUSIONS: The nurse-led supported self-care intervention was associated with favorable within-participant changes in selected anthropometric and cardiometabolic measures, particularly those related to central adiposity and cardiovascular risk. However, no significant improvement in HbA1c was observed. Controlled studies are needed to determine whether these changes can be attributed to the intervention.

Geriatric nursing (New York, N.Y.) 2026 Nov 7 PubMed
16 Effect of a simulation-based risk perception intervention on glycemic control in community-dwelling older adults with uncontrolled type 2 diabetes: A quasi-experimental study. Seesawang J et al. 10.1016/j.gerinurse.2026.104404
View abstract

OBJECTIVE: This study examined the effect of a simulation-based risk perception intervention on glycemic control and diabetes self-care behaviors in community-dwelling older adults with uncontrolled type 2 diabetes. METHODS: A quasi-experimental pretest-posttest control group design with repeated measures was conducted in Phetchaburi, Thailand. Sixty-two older adults (aged ≥60 years; HbA1c >7%) were pair-matched on age, sex, education, and diabetes duration, forming 31 matched pairs; one member of each pair was assigned to the experimental or control group by coin toss. The 12-week intervention, grounded in Rothman and Kiviniemi's health risk communication framework, combined individual and group sessions using a blood flow simulation model, motivational interviewing, and biweekly follow-up. Data were analyzed using ANCOVA and mixed-design ANOVA. RESULTS: After adjusting for baseline HbA1c, the experimental group showed a statistically significant reduction in HbA1c at Week 12 than controls (adjusted means 7.67 vs. 7.97; F(1,59)=75.63, p<.001, partial η²=0.56). A statistically significant time × group interaction was observed for overall self-care behaviors (F(2120)=43.21, p<.001, partial η²=0.41) and all four subdomains. CONCLUSIONS: A simulation-based risk perception intervention was associated with statistically significant improvements in glycemic control and self-care behaviors among older adults with uncontrolled diabetes, although the HbA1c reduction fell below the minimal clinically important difference. This nurse-assisted approach shows potential for future implementation in community and primary care settings; however, feasibility of delivery by routine primary care nurses amid existing nursing shortages in some localities was not evaluated and warrants further investigation.

Geriatric nursing (New York, N.Y.) 2026 Nov 6 PubMed
17 Chaetomorpha linum (O.F.Müller) Kützing 1845 attenuates glucotoxicity via modulation of polyol pathway, oxidative stress and glucose metabolism in adipose tissue. Magwaza SN et al. 10.1080/14786419.2026.2753100
View abstract

Chronic hyperglycaemia in type 2 diabetes drives a self-perpetuating cycle of glucotoxicity. This study investigated the therapeutic potential of extracts from the green seaweed (O.F.Müller) Kützing, 1845 to mitigate glucotoxicity in rats adipocytes. Liquid chromatography-mass spectrometry (LC-MS) analysis revealed distinct phytochemical profiles, with the aqueous extract containing isolobinine, kurarinol, rutaevin, and proanthocyanidin-A2, and the ethanol extract containing caryoptin, mesembrinol, 12-deoxyphorbol-13-octadecanoate, and aspulvinone H. Bioactivity assays showed that extracts reversed glucotoxicity-induced pathologies, restoring glucose uptake (3.9-6.1 mg/g adipose tissue at 240 µg/mL), suppressing polyol pathway enzyme activities (2.7-9.5 µmol/min/mg, at 240 µg/mL), and enhancing antioxidant defense markers. Concurrently, the extracts inhibited key digestive enzymes (26.7-41.0 µmol/min/µL, at 240 µg/mL). Molecular docking supported these findings, with rutaevin showing the high affinity for aldose reductase (-11.7 kcal/mol) and proanthocyanidin-A2 for lipase (-9.9 kcal/mol) and glutathione peroxidase (-7 kcal/mol). These findings highlight as a promising source of bioactive compounds for diabetes management.

Natural product research 2026 Nov 7 PubMed
18 Initial Diabetes Therapy After Coronary Artery Bypass Grafting and Long-Term Outcomes. Tam V et al. 10.1161/JAHA.126.053850
View abstract

BACKGROUND: Type 2 diabetes (T2D) is common among patients undergoing coronary artery bypass grafting (CABG), but optimal post-CABG glucose-lowering therapy remains uncertain. METHODS: We conducted a retrospective cohort study using the OptumLabs Data Warehouse of adults with T2D undergoing isolated CABG from 2012-2024. Follow-up began 30 days after discharge. Glucose-lowering therapy was modeled as a time-varying exposure with patients contributing no-observed-therapy person-time until the first qualifying post-discharge fill. Pairwise comparisons used stabilized inverse probability of treatment weighting. The primary outcome was all-cause mortality; secondary outcomes were heart failure hospitalization, stroke, and repeat coronary revascularization. RESULTS: Among 19,237 patients, 24.9% had no observed post-discharge therapy, 42.8% received metformin, 22.9% received insulin, and 9.4% received GLP-1RA/SGLT2i therapy. All active therapies were associated with lower mortality compared with no observed therapy, including GLP-1RA/SGLT2i (HR 0.71, 95% CI 0.58-0.87), metformin (HR 0.60, 95% CI 0.55-0.66), and insulin (HR 0.75, 95% CI 0.67-0.84). Among active therapies, metformin was associated with lower mortality than insulin (HR, 0.61 [0.54-0.70]); GLP-1RA/SGLT2i comparisons with metformin and insulin were less precise. Metformin was also associated with lower cumulative incidence of heart failure hospitalization than no observed therapy and insulin, and lower stroke incidence than insulin. CONCLUSIONS: Observed glucose-lowering therapy initiation after CABG was associated with lower mortality compared with no observed therapy across all active treatment groups. These findings highlight a potential care gap and suggest that proper initiation of diabetes therapy after CABG represents an important opportunity to improve long-term outcomes following surgical revascularization.

Journal of the American Heart Association 2026 Nov 7 PubMed
19 Correction: A modality-aware CRISPR actionability framework for functional prioritization of genome-wide significant type 2 diabetes loci. Mohd MU et al. 10.1007/s00438-026-02523-y Molecular genetics and genomics : MGG 2026 Nov 7 PubMed
20 Multivessel Assessment by Angiography-Derived Index of Microcirculatory Resistance in Patients With Nonobstructive Coronary Artery Disease. Lui CL et al. 10.1016/j.jcmg.2026.09.006
View abstract

BACKGROUND: Current guidelines recommend testing for coronary microvascular dysfunction (CMD) in the left anterior descending coronary artery, and it is unclear whether multivessel assessment can improve the diagnostic yield and prognostic value of CMD. OBJECTIVES: The aim of this study was to evaluate the diagnostic and prognostic implications of multivessel CMD assessment using angiography-derived index of microcirculatory resistance (angio-IMR) in patients with nonobstructive coronary artery disease (NOCAD). METHODS: Angio-IMR was measured in all 3 major coronary arteries in 439 patients with NOCAD. Single-vessel assessment was defined as angio-IMR measurement in the left anterior descending coronary artery only. Multivessel assessment was defined as angio-IMR measurement in all 3 major coronary arteries. The primary endpoint was major adverse cardiovascular events, comprising a composite of cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure. RESULTS: Multivessel assessment identified more patients with CMD than single-vessel assessment (46.7% vs 24.1%; P < 0.001). During a median follow-up period of 4.3 years, an increased number of vessels with CMD was associated with a higher risk for major adverse cardiovascular events after adjustment for diabetes mellitus, smoking, hypertension, hyperlipidemia, and history of myocardial infarction (adjusted HR: 1.963 per vessel; 95% CI: 1.513-2.548; P < 0.001). Multivessel assessment showed superior prognostic performance compared with single-vessel assessment when added to a clinical risk factor model (area under the curve: 0.751 vs 0.707; P = 0.034). CONCLUSIONS: Multivessel assessment by angio-IMR improved the diagnostic yield of CMD and added incremental prognostic information compared with single-vessel assessment in patients with NOCAD.

JACC. Cardiovascular imaging 2026 Nov 5 PubMed
21 Burden of Albuminuria in US Adults and its Association with Obesity, Sex and Mortality: A Cross-sectional Analysis of NHANES 2003-2020. Batool A et al. 10.1152/ajprenal.90014.2026
View abstract

INTRODUCTION: Albuminuria is an early marker of kidney disease diagnosis, severity and progression. Obesity, a major public health concern in the United States, may contribute to the development of albuminuria; however, the obesity-albuminuria relationship remains incompletely defined. We hypothesized that albuminuria is more prevalent in obese individuals and is associated with poor survival. METHODS: We conducted a cross-sectional analysis of NHANES survey cycles from 2003 to 2020, with linked mortality data through 2016. The study included 59,717 participants aged ≥18 years with available urinary albumin creatinine ratio (uACR) and BMI ≥18 kg/m. BMI was categorized into normal weight, overweight and obese. Albuminuria was defined as UACR ≥30 mg/g and categorized into three severity grades (mild, moderate, and severe). Logistic regression models were used to assess the association between obesity and albuminuria, and adjustment by sociodemographic and clinical factors was assessed. Survival across albuminuria severity grades was examined. RESULTS: Among individuals with albuminuria the prevalence of obesity was significantly higher than those without albuminuria (40.2% vs 32.9%; p<0.001). Individuals with albuminuria were relatively older and had higher prevalence of diabetes and hypertension as compared to the no albuminuria group. Obesity was significantly associated with higher odds of albuminuria (OR 1.36; 95% CI 1.23-1.50) when controlling for sociodemographic and clinical factors. We also observed higher odds of albuminuria in individuals who were males (OR 1.58, 95% CI 1.37-1.82), ages 18 to 44 years (OR 1.46, 95% CI 1.26-1.68), and ages 45 to 64 years (OR 1.79, 95% CI 1.49-2.14). The Individuals with albuminuria had poorer survival, with stark decline in a stepwise manner across albuminuria severity grades. CONCLUSION: Obesity is strongly associated with albuminuria in U.S. adults. Albuminuria is linked to survival disadvantage, underscoring the importance of screening among individuals with obesity and early initiation of nephro-protective therapies in individuals with albuminuria.

American journal of physiology. Renal physiology 2026 Nov 7 PubMed
22 SGLT-2 Inhibitors versus GLP-1 Receptor Agonists for Dementia and Depression in Type 2 Diabetes Mellitus: A Meta-Analysis. Pan R et al. 10.2147/DMSO.S628886
View abstract

BACKGROUND: The comparative effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on dementia and depression risk in patients with type 2 diabetes mellitus (T2DM) remain unclear. We conducted a meta-analysis to directly compare the incidence of dementia and depression-related outcomes between users of these two drug classes. METHODS: A systematic literature search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from inception to June 1, 2026. Observational studies reporting quantifiable data on dementia or depression-related events in adults with T2DM were included. Detailed information on study design, age, demographic characteristics, eligibility criteria, outcome definitions, and outcome incidence was extracted. Data were pooled using a random-effects model to calculate odds ratios (ORs) with 95% confidence intervals (CIs). Sensitivity analyses involved sequential exclusion of individual studies. Prespecified subgroup analyses examined effect modifiers including geographic region, study design, age, and follow-up duration. Study quality was assessed using the Newcastle-Ottawa Scale, and the overall certainty of evidence and methodological rigor of this meta-analysis were evaluated using the AMSTAR 2 checklist. RESULTS: Thirteen observational studies comprising 1,055,315 participants were included. Compared with GLP-1RA users, SGLT-2i users had lower rates of all-cause dementia (OR 0.85, 95% CI 0.77-0.94; P = 0.001), vascular dementia (OR 0.75, 95% CI 0.71-0.80; P < 0.001), Alzheimer's disease (OR 0.76, 95% CI 0.72-0.79; P < 0.001), and composite depression-related outcomes (OR 0.76, 95% CI 0.67-0.88; P = 0.001), including suicide/self-harm (OR 0.69, 95% CI 0.60-0.80; P < 0.001) and depression/anxiety (OR 0.78, 95% CI 0.65-0.93; P = 0.006). Subgroup analyses revealed more pronounced differences in Asian populations (dementia: OR 0.86, 95% CI 0.75-0.99; I = 0%), European cohorts (depression: OR 0.67, 95% CI 0.54-0.84; I = 83%), and in studies that enrolled younger adults (minimum age 18 years, without an upper age restriction) (dementia: OR 0.79, 95% CI 0.76-0.81; I = 0%; depression: OR 0.67, 95% CI 0.54-0.84; I = 83%). CONCLUSIONS: In this meta-analysis of observational studies, SGLT-2i use was associated with lower rates of dementia and depression-related outcomes compared with GLP-1RA use in patients with T2DM. Age and geographic region may influence the observed associations. Future randomized controlled trials and studies reporting outcomes stratified by sex, socioeconomic status, and educational level are warranted.

Diabetes, metabolic syndrome and obesity : targets and therapy 2026 PubMed
23 Gut Microbiota Signaling Axes as Candidate Therapeutic Targets in Type 2 Diabetes Mellitus: Mechanistic Crosstalk and Translational Challenges. Zhang Y et al. 10.2147/DMSO.S646274
View abstract

Gut microbiota disturbance serves as a critical pathogenic factor for metaflammation (metabolic inflammation) and insulin resistance in type 2 diabetes mellitus (T2DM). Growing preclinical evidence demonstrates that gut microbial metabolites modulate systemic metabolic and immune homeostasis via multiple interactive signaling axes rather than independent single pathways. This narrative review systematically summarizes four core signaling axes derived from gut microbiota. These axes include the SCFAs-AMPK energy-sensing axis, the BA- FXR/TGR5 metabolic regulatory axis, the LPS-TLR4/NF-κB proinflammatory axis, and the tryptophan-AhR intestinal barrier repair axis. This work further discusses the crosstalk among these axes and their potential functional roles in T2DM progression. We propose that intestinal metabolic and immune homeostasis relies on the dynamic balance between protective metabolic pathways and proinflammatory injury pathways. Consistent with cumulative preclinical findings, the NF-κB/NLRP3 inflammasome complex acts as a potential downstream convergence node. This node integrates upstream microbial metabolic disorders, amplifies chronic low-grade inflammatory cascades, and subsequently induces intestinal barrier impairment, insulin resistance and T2DM deterioration.This review further defines two conceptual regulatory patterns of relevant signaling networks. One is the synergistic homeostatic protection dominated by energy-sensing pathways, and the other is the antagonistic pathological imbalance triggered by excessive inflammatory activation. This study also highlights major existing limitations in current research. These limitations involve insufficient investigations into multimodule crosstalk, ambiguous spatiotemporal regulatory characteristics of core inflammatory hubs, and inadequate clinical translational validation. In conclusion, the dysregulation of multiple interactive signaling axes disrupts metabolic and immune homeostasis, which constitutes a preclinically validated upstream pathogenic mechanism for T2DM and requires further comprehensive verification in human clinical cohorts. Conventional therapeutic strategies focus on single-target intervention. The transformation toward precise combinatorial strategies targeting the gut microbiota-associated multi-signal network can provide novel theoretical references and translational directions for early intervention and holistic management of T2DM. Nevertheless, clinical evidence supporting simultaneous multi-axis targeted intervention remains insufficient.

Diabetes, metabolic syndrome and obesity : targets and therapy 2026 PubMed
24 Toward Immersive Diabetes Education: Understanding User Needs for Virtual Reality-Assisted Self-Management Support in Adults With Type 2 Diabetes Mellitus. Jafar N et al. 10.1155/nrp/4385505
View abstract

Effective self-management in Type 2 diabetes mellitus (T2DM) requires sustained adherence to diet, physical activity, medication, and lifestyle modification. However, conventional diabetes education often remains generic, one-directional, and insufficiently responsive to the psychological, behavioral, and contextual challenges patients face in daily life. Immersive technologies such as virtual reality (VR) may offer a more engaging approach to diabetes education, yet evidence on the user needs that should inform such interventions remains limited. This study explored the psychological, behavioral, and educational needs of adults with T2DM and healthcare providers to inform the development of VR-assisted self-management support. A qualitative descriptive study was conducted involving adults with T2DM ( = 12) and healthcare providers ( = 6), purposively recruited based on their experience in diabetes self-management or care; prior technology experience was not required. Data were collected through in-depth interviews and analyzed using thematic analysis. Seven interrelated themes were identified: (1) psychological experiences of living with and managing diabetes, (2) motivation and adherence, (3) adaptation of physical activity, (4) dietary management challenges, (5) limitations of current diabetes education, (6) educational needs supporting self-management, and (7) VR as an alternative educational medium. Participants described emotional distress, uncertainty, adherence fatigue, and difficulty translating advice into daily behaviors. Existing education was often perceived as overly general, medically framed, and insufficiently tailored to real-life needs. Both patients and healthcare providers preferred education that is simple, interactive, practical, and grounded in everyday experiences. VR was viewed as a potentially valuable medium for simulating realistic self-management scenarios, although concerns regarding usability and complexity were also raised. These findings provide a user-centered qualitative foundation for developing immersive VR-assisted diabetes self-management support, intended to complement conventional education; its feasibility, sustainability, and effectiveness remain to be evaluated.

Nursing research and practice 2026 PubMed
25 Deep Learning on Satellite Imagery Reveals Landscape Drivers of Metabolic Syndrome. Chen R et al. 10.1021/EHP.6c00354
View abstract

BACKGROUND: Understanding how environmental contexts influence metabolic syndrome (MetS) is limited by conventional exposure metrics that fail to capture complex, visually perceived neighborhood features. We aimed to develop a satellite-based deep learning framework to characterize fine-scale environmental exposures and examine their associations with MetS. METHODS: We developed VISTAnet to extract latent geographic features from 49,050 high-resolution satellite images and identified eight landscape types through unsupervised clustering. 1,34,675 adults from Deqing, China, were included in this study. For each participant, environmental exposure was quantified as the Isochrone Landscape Proportion (ILP) within a 15 min walking isochrone around the residence. Associations between ILP and MetS were evaluated using mixed-effects logistic regression models. Stratified analyses were conducted by age, sex, educational level, employment status, and community type, and sensitivity analyses were conducted to assess the robustness of the findings. RESULTS: Greater exposure to nature-dominated environments was associated with lower odds of MetS. Participants in the highest exposure quartile had significantly lower odds of having MetS for (adjusted odds ratio [aOR] 0.818, 95% CI 0.728-0.918), (0.941, 0.901-0.983), and (0.838, 0.798-0.881). In contrast, higher exposure to (1.101, 1.058-1.145) and (1.203, 1.151-1.257) was associated with increased odds of MetS. Findings were robust in sensitivity analyses. CONCLUSIONS: Nature-dominated landscapes were linked to lower MetS risk, whereas dense residential and industrial environments were linked to higher risk. This framework may support scalable environmental health assessment and health-oriented urban planning.

Environmental health perspectives 2026 Nov 3 PubMed
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Diabetes (Type 2)
  • Week: November 2 – November 9, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 15, 2026 at 10:18 PM
© 2026 DoctiPlus Care Vol. 7 · No. 46 · November 15, 2026 — 30 —